NCT00611676View on ClinicalTrials.gov

A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
OsteoarthritisPain
Interventions
DRUG

Venlafaxine

Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

University of Washington

OTHER

NCT00611676 - A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain | Biotech Hunter | Biotech Hunter